IRB #

STUDY00016058

Title

CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer
(CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)

Principal Investigator

Gina Vaccaro

Study Purpose

To assess the effectiveness of nivolumab (study drug) in adults with resected esophageal and gastroesophageal junction cancer

Medical Condition(s)

resected esophageal cancer
resected gastroesophageal junction cancer

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer at the time of initial diagnosis
3. Must have complete resection, have been surgically rendered free of disease

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment will continue for no longer than one year, until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be contacted by phone every 3 months until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
knight@ohsu.edu

Sponsor

Bristol-Myers Squibb

Recruitment End

12/31/2030

Compensation Provided

No


Go Back